Diagnostic role of CXCL13 biomarker in primary Sjogren's syndrome patients with parotid non-Hodgkin's lymphoma complication

Introduction: Serum biomarkers are important predictive factors for development of parotid non-Hodgkin's lymphoma (NHL) complication in primary Sjogren's syndrome (pSS) patients. The aim was to evaluate the diagnostic accuracy of serum CXCL13 chemokine in pSS patients with parotid NHL complication.Material and methods: Serum CXCL13 chemokine was assessed in 33 patients with pSS [7 with parotid NHL complication (pSS + NHL subgroup) and 26 without NHL (pSS-NHL subgroup)] and 30 healthy subjects.Results: The serum CXCL13 levels in pSS + NHL subgroup [175.2 (107.9-220.4) pg/ml] were significantly higher comparing to the healthy subjects group (p = 0.018) and the pSS-NHL subgroup (p = 0.048). A cut-off value of 123.45 pg/ml (Se = 71.4%, Sp = 80.8%, AUROC = 0.747) was established for parotid lymphoma diagnosis.Conclusion: The serum CXCL13 biomarker could be considered a valuable tool for the diagnosis of parotid NHL complication in pSS patients.& COPY; 2023 Elsevier Espan & SIM;a, S.L.U. All rights reserved.